MY162514A - Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors - Google Patents
Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitorsInfo
- Publication number
- MY162514A MY162514A MYPI2012000838A MYPI2012000838A MY162514A MY 162514 A MY162514 A MY 162514A MY PI2012000838 A MYPI2012000838 A MY PI2012000838A MY PI2012000838 A MYPI2012000838 A MY PI2012000838A MY 162514 A MY162514 A MY 162514A
- Authority
- MY
- Malaysia
- Prior art keywords
- taxane
- combination therapy
- nanoparticle compositions
- hedgehog inhibitors
- hedgehog
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
THE PRESENT INVENTION PROVIDES COMBINATION THERAPY METHODS OF TREATING A PROLIFERATIVE DISEASE (SUCH AS CANCER) COMPRISING ADMINISTERING TO AN INDIVIDUAL AN EFFECTIVE AMOUNT OF A TAXANE IN A NANOPARTICLE COMPOSITION, AND A HEDGEHOG INHIBITOR THAT INHIBITS A HEDGEHOG SIGNALING PATHWAY.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23681309P | 2009-08-25 | 2009-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY162514A true MY162514A (en) | 2017-06-15 |
Family
ID=43628371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2012000838A MY162514A (en) | 2009-08-25 | 2010-08-25 | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
Country Status (27)
Country | Link |
---|---|
US (2) | US20130045240A1 (en) |
EP (2) | EP2470173B1 (en) |
JP (1) | JP2013503174A (en) |
KR (1) | KR20120053052A (en) |
CN (1) | CN102573832B (en) |
AU (1) | AU2010286670B2 (en) |
BR (1) | BR112012004149A2 (en) |
CA (1) | CA2772301A1 (en) |
CR (1) | CR20120115A (en) |
DK (1) | DK2470173T3 (en) |
ES (1) | ES2577024T3 (en) |
HK (1) | HK1172550A1 (en) |
HR (1) | HRP20160551T8 (en) |
HU (1) | HUE029094T2 (en) |
IL (1) | IL218316A (en) |
IN (1) | IN2012DN02018A (en) |
MX (1) | MX340670B (en) |
MY (1) | MY162514A (en) |
NI (1) | NI201200030A (en) |
NZ (1) | NZ598588A (en) |
PL (1) | PL2470173T3 (en) |
PT (1) | PT2470173E (en) |
RU (1) | RU2561055C2 (en) |
SG (2) | SG10201609290PA (en) |
UA (1) | UA110196C2 (en) |
WO (1) | WO2011025838A1 (en) |
ZA (1) | ZA201201531B (en) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
CN104587479A (en) | 2002-12-09 | 2015-05-06 | 阿布拉西斯生物科学有限责任公司 | Compositions and methods of delivery of pharmacological agents |
MX339142B (en) | 2005-02-18 | 2016-05-13 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy. |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
EP3659589A1 (en) * | 2005-08-31 | 2020-06-03 | Abraxis BioScience, LLC | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
EP2117520B1 (en) * | 2006-12-14 | 2018-08-29 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
SI2131821T1 (en) * | 2007-03-07 | 2018-11-30 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
ES2435452T3 (en) * | 2007-06-01 | 2013-12-19 | Abraxis Bioscience, Llc | Methods and compositions to treat recurrent cancer |
EP2942346B1 (en) | 2009-02-17 | 2020-05-06 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as cxcr2 modulators |
DK2419732T3 (en) | 2009-04-15 | 2019-12-16 | Abraxis Bioscience Llc | NON-PARTICLE NON-PARTICLE COMPOSITIONS AND PROCEDURES |
KR101786142B1 (en) * | 2010-03-26 | 2017-10-17 | 아브락시스 바이오사이언스, 엘엘씨 | Methods of treatment of hepatocellular carcinoma |
BR112012024590A2 (en) | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | methods of enhancing drug release and efficacy of therapeutic agents |
RU2589513C2 (en) | 2010-03-29 | 2016-07-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Methods of treating oncological diseases |
AU2011245441B2 (en) | 2010-04-29 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
WO2011153009A1 (en) * | 2010-06-02 | 2011-12-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
KR20180049180A (en) * | 2010-06-04 | 2018-05-10 | 아브락시스 바이오사이언스, 엘엘씨 | Methods of treatment of pancreatic cancer |
RU2016103126A (en) * | 2010-06-07 | 2018-11-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | METHODS OF COMBINED THERAPY FOR TREATMENT OF PROLIFERATIVE DISEASES |
JP6486002B2 (en) | 2010-08-23 | 2019-03-20 | シントリックス・バイオシステムズ・インコーポレイテッドSyntrix Biosystems, Inc. | Aminopyridine carboxamide and aminopyrimidine carboxamide as CXCR2 modulators |
WO2012149451A1 (en) | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
US8945627B2 (en) | 2011-05-05 | 2015-02-03 | Wisconsin Alumni Research Foundation | Micelles for the solubilization of gossypol |
DK2790675T3 (en) | 2011-12-14 | 2019-09-09 | Abraxis Bioscience Llc | APPLICATION OF POLYMER EXCIPIENTS FOR FREEZING DRY OR FREEZING OF PARTICLES |
WO2013112859A1 (en) | 2012-01-27 | 2013-08-01 | New York University | Method for enhancing remyelination using gli1 inhibitors |
CN103570625A (en) * | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-aryl-heteroaryl)-4-aryl-aryl carboxamide and analog as hedgehog pathway inhibitors and application thereof |
CA2888360A1 (en) * | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
WO2014087413A1 (en) * | 2012-12-03 | 2014-06-12 | Vishwa Vidya Peetham University Amrita | Nanoparticles comprising sorafenib |
US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
CN105246468A (en) | 2013-03-14 | 2016-01-13 | 阿布拉科斯生物科学有限公司 | Methods of treating bladder cancer |
US9045477B2 (en) | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
US9776996B2 (en) | 2013-03-15 | 2017-10-03 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
WO2014179678A1 (en) * | 2013-05-03 | 2014-11-06 | Angiostrass Llc | Methods of treating cancer and angioproliferative disorders |
AU2014275643B2 (en) | 2013-06-05 | 2018-08-09 | C&C Research Laboratories | Heterocyclic derivatives and use thereof |
WO2015002926A1 (en) | 2013-07-02 | 2015-01-08 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
TW201506024A (en) | 2013-07-02 | 2015-02-16 | 必治妥美雅史谷比公司 | Tricyclic carboxamide derivatives as potent ROCK inhibitors |
WO2015003360A2 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
CA2922889A1 (en) | 2013-09-17 | 2015-03-26 | Genentech, Inc. | Methods of using anti-lgr5 antibodies |
GB201416513D0 (en) | 2014-09-18 | 2014-11-05 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
CN111170998B (en) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | Pyrimidine or pyridine compound, preparation method and medical application thereof |
KR20160066490A (en) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | Heterocyclic derivatives and use thereof |
CN107530304A (en) | 2015-02-27 | 2018-01-02 | 科泰纳制药公司 | The suppression of OLIG2 activity |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
WO2016198691A1 (en) | 2015-06-11 | 2016-12-15 | Basilea Pharmaceutica Ag | Efflux-pump inhibitors and therapeutic uses thereof |
CN108024999A (en) | 2015-06-29 | 2018-05-11 | 阿布拉科斯生物科学有限公司 | The method for treating epithelioid cell's tumour |
CN106421786A (en) * | 2015-08-06 | 2017-02-22 | 复旦大学 | Hedgehog pathway inhibitor and nanometer drug delivery system pharmaceutical composition and uses thereof |
JP2018052878A (en) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | Pyridine compound |
US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
BR112020018910A2 (en) | 2018-03-20 | 2020-12-29 | Abraxis Bioscience, Llc | METHODS OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER THROUGH THE ADMINISTRATION OF NANOPARTICLES FROM A UNITER OF MTOR AND AN ALBUMIN |
JP2022543021A (en) * | 2019-05-29 | 2022-10-07 | ネルム コーポレーション | Methods and uses for treating cancer |
KR20220106758A (en) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | Pharmaceutical Compositions of Albumin and Rapamycin |
CN112755042A (en) * | 2019-11-06 | 2021-05-07 | 绍兴维帆生物技术有限公司 | Method for treating leukemia by using antitumor drugs in combination |
KR102526793B1 (en) * | 2021-11-03 | 2023-04-28 | 주식회사 에스엔바이오사이언스 | Method for preparing albumin bound taxane nanoparticles with improved particle size distribution maintenance stability |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070117863A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
SG113402A1 (en) * | 1997-06-27 | 2005-08-29 | American Bioscience Inc | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
DE69939327D1 (en) | 1998-11-02 | 2008-09-25 | Curis Inc | FUNCTIONAL ANTAGONISTS OF HEDGEHOG ACTIVITY |
US6291516B1 (en) | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
AU767066B2 (en) | 1999-03-03 | 2003-10-30 | Curis, Inc. | Methods of modulating lipid metabolism and storage |
JP2003502292A (en) | 1999-06-01 | 2003-01-21 | バイオジェン インコーポレイテッド | Polymer conjugates and uses of hedgehog proteins |
US7708998B2 (en) | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
US20050192262A1 (en) * | 2001-03-13 | 2005-09-01 | Tomas Hagstrom | Treatment of tumours |
EA007339B1 (en) | 2001-07-27 | 2006-08-25 | Кьюэрис, Инк. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
ITMI20020680A1 (en) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | IMPROVED ANTI-TUMOR COMPOSITION BASED ON PACLITAXEL AND METHOD FOR ITS OBTAINING |
EP1496905B1 (en) | 2002-04-22 | 2008-08-13 | Johns Hopkins University School of Medicine | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
CN104587479A (en) | 2002-12-09 | 2015-05-06 | 阿布拉西斯生物科学有限责任公司 | Compositions and methods of delivery of pharmacological agents |
FR2850022B1 (en) * | 2003-01-22 | 2006-09-08 | Centre Nat Rech Scient | NOVEL USE OF MIFEPRISTONE AND ITS DERIVATIVES AS MODULATORS OF THE HEDGEHOG PROTEIN SIGNALING PATH AND ITS APPLICATIONS |
PE20050206A1 (en) * | 2003-05-26 | 2005-03-26 | Schering Ag | PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF HISTONE DEACETILASE |
WO2006039569A1 (en) * | 2004-09-30 | 2006-04-13 | The University Of Chicago | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents |
AU2005301962B2 (en) * | 2004-11-03 | 2011-10-20 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
MX339142B (en) | 2005-02-18 | 2016-05-13 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy. |
CA2620389C (en) | 2005-08-31 | 2014-06-17 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
US20070117815A1 (en) * | 2005-11-04 | 2007-05-24 | James Pluda | Method of treating cancers with SAHA and pemetrexed |
AR054215A1 (en) * | 2006-01-20 | 2007-06-13 | Eriochem Sa | A PHARMACEUTICAL FORMULATION OF A TAXANE, A SOLID COMPOSITION OF A LIOFILIZED TAXAN FROM AN ACETIC ACID SOLUTION, A PROCEDURE FOR THE PREPARATION OF A SOLID COMPOSITION OF A TAXANE, A SOLUBILIZING COMPOSITION OF A LIOFILIZED TAXANE AND AN ELEMENTARY KIT |
WO2008121102A2 (en) | 2006-02-21 | 2008-10-09 | The Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
DE102006038747A1 (en) | 2006-08-17 | 2008-03-20 | Khs Ag | Sealing arrangement for a rotary bearing device |
JP4897518B2 (en) | 2007-03-02 | 2012-03-14 | 株式会社ニチベイ | Blind operating device |
CA2680796A1 (en) * | 2007-03-14 | 2008-09-18 | Exelixis, Inc. | Inhibitors of the hedgehog pathway |
US8536168B2 (en) * | 2007-03-15 | 2013-09-17 | Novartis Ag | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway |
US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
ES2569941T3 (en) * | 2007-06-07 | 2016-05-13 | Novartis Ag | Biphenylcarboxamide derivatives as hedgehog path modulators |
US20090123932A1 (en) * | 2007-11-09 | 2009-05-14 | Anne-Marie Mes-Masson | Quantitative test to detect disease progression markers of epithelial ovarian cancer patients |
CN101918420A (en) | 2007-12-27 | 2010-12-15 | 无限药品股份有限公司 | Therapeutic cancer treatments |
WO2009086324A1 (en) * | 2007-12-28 | 2009-07-09 | Genentech, Inc. | Anti-hedgehog antibodies |
-
2010
- 2010-08-25 UA UAA201203446A patent/UA110196C2/en unknown
- 2010-08-25 US US13/392,501 patent/US20130045240A1/en not_active Abandoned
- 2010-08-25 HU HUE10812593A patent/HUE029094T2/en unknown
- 2010-08-25 RU RU2012111235/15A patent/RU2561055C2/en active
- 2010-08-25 SG SG10201609290PA patent/SG10201609290PA/en unknown
- 2010-08-25 WO PCT/US2010/046684 patent/WO2011025838A1/en active Application Filing
- 2010-08-25 DK DK10812593.1T patent/DK2470173T3/en active
- 2010-08-25 AU AU2010286670A patent/AU2010286670B2/en active Active
- 2010-08-25 CA CA2772301A patent/CA2772301A1/en not_active Abandoned
- 2010-08-25 CN CN201080045983.0A patent/CN102573832B/en active Active
- 2010-08-25 PL PL10812593.1T patent/PL2470173T3/en unknown
- 2010-08-25 SG SG2012013157A patent/SG178873A1/en unknown
- 2010-08-25 JP JP2012526948A patent/JP2013503174A/en active Pending
- 2010-08-25 EP EP10812593.1A patent/EP2470173B1/en active Active
- 2010-08-25 MY MYPI2012000838A patent/MY162514A/en unknown
- 2010-08-25 PT PT108125931T patent/PT2470173E/en unknown
- 2010-08-25 EP EP16167017.9A patent/EP3103452A1/en not_active Withdrawn
- 2010-08-25 BR BR112012004149A patent/BR112012004149A2/en not_active Application Discontinuation
- 2010-08-25 NZ NZ598588A patent/NZ598588A/en not_active IP Right Cessation
- 2010-08-25 MX MX2012002460A patent/MX340670B/en active IP Right Grant
- 2010-08-25 ES ES10812593.1T patent/ES2577024T3/en active Active
- 2010-08-25 KR KR1020127007526A patent/KR20120053052A/en not_active Application Discontinuation
- 2010-08-25 IN IN2018DEN2012 patent/IN2012DN02018A/en unknown
-
2012
- 2012-02-24 NI NI201200030A patent/NI201200030A/en unknown
- 2012-02-26 IL IL218316A patent/IL218316A/en active IP Right Grant
- 2012-02-29 ZA ZA2012/01531A patent/ZA201201531B/en unknown
- 2012-03-12 CR CR20120115A patent/CR20120115A/en unknown
- 2012-12-24 HK HK12113319.3A patent/HK1172550A1/en unknown
-
2013
- 2013-02-28 US US13/781,487 patent/US20140072630A1/en not_active Abandoned
-
2016
- 2016-05-23 HR HRP20160551TT patent/HRP20160551T8/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY162514A (en) | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors | |
MY162903A (en) | Methods of treatment of pancreatic cancer | |
NZ593343A (en) | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor | |
MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
PH12016502066A1 (en) | Methods of treating bladder cancer | |
MX2020010535A (en) | Methods of treating cancer. | |
MX2019010601A (en) | Combination therapy for treating cancer. | |
MX346861B (en) | Methods of treatment of hepatocellular carcinoma. | |
MX2016007351A (en) | Combination therapy for treating cancer. | |
PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
MX346147B (en) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use. | |
CR20120202A (en) | METHODS AND COMPOSITIONS TO TREAT CANCER | |
PH12013502370A1 (en) | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
CO6321188A2 (en) | CANCER TREATMENT WITH COMBINATIONS OF TOPOISOMERASA INHIBITORS AND PARP INHIBITORS | |
TN2011000414A1 (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitors, and uses thereof | |
MX2013011908A (en) | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors. | |
GB201114051D0 (en) | Compounds and their uses | |
UA103614C2 (en) | Medicinal composition for treating hepatic cancer which comprises a kinase inhibitor. combined with glypican 3 antibody | |
MY153948A (en) | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof | |
MX2013006319A (en) | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer. | |
EP2576536A4 (en) | Haematopoietic-prostaglandin d2 synthase inhibitors | |
MX2014006662A (en) | Targeting en2, pax2, and/or defb1 for treatment of prostate conditions. | |
MX2014010749A (en) | Gynecologic composition to treat vulvar vestibulitis. | |
GB201312583D0 (en) | Combination and composition for treating obesity | |
MX2012010006A (en) | A3ar agonists for the treatment of uveitis. |